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Background: Human obesity has been associated with alterations of vascular structure, especially in large and
medium arteries, but the effects of insulin-sensitizers are not well known.
Methods: Twenty-ﬁve maleWistar rats received subcutaneous injections of monosodium glutamate (MSG) or
an equivalent volume of vehicle from the second to the sixth day after birth, At 16 weeks of age, ﬁve MSG rats
started receiving an oral treatment with metformin (300 mg/kg) which was maintained for six weeks, com-
posing ﬁve groups: control 16 weeks (CON-16), MSG 16 weeks (MSG-16), control 22 weeks (CON-22), MSG
22 weeks (MSG-22), and MSG plus metformin 22 weeks (MET-22). Systolic blood pressure (BP) was veriﬁed
weekly. The lumen diameter and media thickness, media cross-sectional area (CSA) and growth index of the
intramyocardial arterioles were measured. Cardiac interstitial and perivascular collagen density were also
evaluated.
Results: Systolic BP was signiﬁcantly increased in the MSG-22 comparing to MSG-16 group. Insulin resistance
was conﬁrmed by HOMA-IR index and metformin-treated group presented reduction of insulin levels at
week 22. The morphology analysis showed greater media-to-lumen ratio and CSA in the obese groups,
which were reduced by the metformin treatment. Connective tissue deposition in the perivascular region
of the left ventricle was signiﬁcantly higher in the obese groups which was attenuated by metformin.
Conclusions: Hypertrophic vascular remodeling and cardiac collagen deposition were signiﬁcantly evident in
MSG-induced obese rats. Metformin treatment was able to reduce insulin resistance and attenuated this ad-
verse cardiac and vascular remodeling.
© 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license. 1. Introduction
The prevalence of overweight and obesity has markedly increased
over the past two decades, growing rapidly fromWestern societies to
the rest of the world [1,2]. The INTERHEART study demonstrated that
obesity is one of the nine modiﬁable risk factors accounting for more
than 90% of myocardial infarction risk [3]. Thus, considering obesity
as a risk factor for cardiovascular disease, the comprehension of un-
derlying pathological changes linking obesity with heart disease is es-
sential. A recent evaluation of Framingham Study participants
stratiﬁed by body mass index and waist circumference indicated that
individuals with generalized or abdominal obesity had a high preva-
lence of subclinical disease which partly contributed to the increased
cardiovascular risk associated with excess adiposity in these subjects
[4].
Recent studies have shown that human obesity is associated with
alterations of vascular structure and function, especially in large and
medium arteries [5,6]. Structural alterations of subcutaneous small
resistance arteries, as indicated by an increased media-to-lumenio de Janeiro, Centro Biomédico,
nicaMédica, Av 28 de Setembro
2587 6633.
nder the Elsevier OA license. ratio, are frequently present in hypertensive and or/diabetic patients.
These vascular changes may represent the earliest alterations in these
subjects and present a strong prognostic signiﬁcance [7,8]. In severe
obese normotensive subjects, Grassi et al. recently showed that sub-
cutaneous small resistance arteries undergo profound structural
modiﬁcations characterized by a hypertrophic process, probably sec-
ondary to vascular smooth muscle cell growth [9].
The administration of monosodium glutamate (MSG) to newborn
rats provokes hypothalamic injury, leading to neuronal loss that im-
pairs insulin and leptin signaling resulting in obesity [10,11]. The
MSG-induced obesity model exhibits most features observed in
human obesity such as abdominal obesity, insulin resistance, and
hyperinsulinemia. In fact, even obese mice induced by MSG have
already been considered a useful experimental model for developing
insulin resistance [12]. In these animals, fat accumulation and insulin
resistance contribute to alterations in microvascular reactivity inde-
pendently of the presence of type 2 diabetes or hypertension [13].
In addition to its insulin-sensitizing effects, previous data indicate
that metformin improves vascular function through a direct mecha-
nism rather than by restoring metabolic abnormalities [14]. Thus, it
seems that metformin has a direct effect predominantly on vascular
function. The precise mechanism is still unidentiﬁed, but it appears
that metformin promotes increased peripheral glucose disposal at
lower insulin concentrations. Interestingly, the use of metformin in
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food intake and weight loss with reduction in fasting plasma glucose,
and insulin concentrations [15]. So we hypothesized that metformin
is able to attenuate some adverse effects of obesity induced by MSG
on cardiac vascular and perivascular structures. Thus, in this study
we investigated the effects of metformin on cardiovascular remodel-
ing and collagen deposition in rats that developed insulin resistance
and central deposits of fat after MSG treatment.2. Material and methods
This protocol was approved by the Ethical Committee for Animal Research of the
Institute of Biomedical Sciences, University of Sao Paulo (Protocol n. 007/04) and con-
forms to the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-
23, revised 1996). Twenty-ﬁve male Wistar rats received subcutaneous injections of
MSG (4.0 mg/g body weight) dissolved in 0.9% NaCl or an equivalent volume of vehicle
from the second to the sixth day after birth. At 16 weeks of age, ﬁve MSG rats started
receiving an oral treatment with metformin (300 mg/kg) which was maintained for
six weeks. Thus, the study was composed by ﬁve groups (n=5 for each): control
16 weeks (CON-16), monosodium glutamate 16 weeks (MSG-16), control 22 weeks
(CON-22), monosodium glutamate 22 weeks (MSG-22), and monosodium glutamate
plus metformin 22 weeks (MET-22). Systolic blood pressure (BP) was veriﬁed weekly
in conscious rats through the non-invasive method of the tail cuff plethysmography
(Letica LE 5100, Panhab, Barcelona, Spain). The average of three pressure readings
was obtained.2.1. Image analysis of the vascular structure
After sacriﬁce, the heart was removed and fragments of the left ventricle were
placed for 48 h at room temperature in ﬁxative (formaldehyde 4% in 0.1 M phosphate
buffer pH 7.2) [16], and then embedded in Paraplast plus (Sigma, St. Louis, USA), sec-
tioned at 5 μm thickness, and stained with hematoxylin–eosin and picro sirius red. Five
ﬁelds per section, ﬁve sections per organ, totaling 125 ﬁelds per group were analyzed
by video microscopy. The lumen diameter and media thickness of the intramyocardial
arterioles that appeared circular on cross section were measured using the Image Pro
Plus analysis software version 5.01 (Media Cybernetics, Silver Spring, USA) in an Olym-
pus BX51 microscope with LC Evolution digital camera. Media cross-sectional area
(CSA) was obtained by subtraction of the internal CSA from external CSA: CSA=
(π/4)×(De2−Di2), where De and Di were external and lumen diameters, respectively.
Growth index was calculated as (CSAt−CSAc)/CSAc, where CSAc and CSAt are media
cross-sectional areas of control and treated (MSG±metformin) vessels, respectively.2.2. Collagen quantiﬁcation in the heart
The heart was ﬁxed and processed for parafﬁn embedding as previously described.
Tissue sections were dewaxed with ethanol and stained with 0.5% Sirius red. Perivas-
cular collagen was normalized by dividing the CSA of intramyocardial arterioles occu-
pied by collagen by the luminal area of the vessel. Interstitial collagen density was
evaluated in two different regions of the LV, including the subepicardial and the suben-
docardial myocardium. From each of 3 nonconsecutive serial sections, about 10 ﬁelds
in each region of the heart were randomly selected and recorded (×20 objective).Table 1
Obesity parameters, vascular morphometry of intramyocardial arterioles and cardiac collag
CON-16 MSG-16
Lee index, % 29.0±0.2 30.4±0.2⁎⁎⁎
Retroperitoneal WAT, g/100 g 0.97±0.07 2.81±0.11⁎
Lumen diameter, μm 32.3±1.7 34.2±3.3
Media thickness, μm 12.6±0.6 14.9±0.9
Media-lumen ratio, % 30.2±2.0 39.9±3.7⁎
Media CSA, ×103μm2 12.5±0.5 14.9±0.9
Growth index, % – 19.2
Myocardial collagen
Subendocardial, % 2.1±0.8 4.1±0.3
Subpericardial, % 2±0.3 3±0.2
Perivascular, % 0.80±0.05 1.19±0.19
Data are expressed in mean±SEM. WAT, white adipose tissue; CSA, cross-sectional area.
⁎ pb0.05 vs respective control groups.
⁎⁎ pb0.01 vs respective control groups.
⁎⁎⁎ pb0.001 vs respective control groups.
## pb0.01 vs MSG-22.3. Data analysis
Values were expressed as mean±SEM. The values were compared
by one-way ANOVA followed by a Tukey post-test. A value of pb0.05
was considered statistically signiﬁcant. All statistical analyses were
performed using Prism forWindows, version 5.0 (GraphPad Software,
Inc.).
4. Results
The Lee index was statistically higher in MSG groups which also
presented greater values of retroperitoneal white adipose tissue
when compared to control groups (Table 1). There was no signiﬁcant
difference in systolic BP when comparing MSG to control groups.
However, the systolic BP was signiﬁcantly increased in the MSG-22
comparing to MSG-16 group (122±2 vs 108±2 mm Hg, pb0.05),
and MET-22 group (118±1 mm Hg) showed lower BP levels without
reaching statistical signiﬁcance (Fig. 1A). At week 16, despite normal
plasma glucose levels, insulin resistance was conﬁrmed as indicated
by a higher HOMA-IR index (Fig. 1B, D). The metformin-treated
group presented reduction of insulin levels and showed improvement
in the insulin resistance tests at week 22 (Fig. 1C, D).
4.1. Vascular structure
The morphology analysis showed similar diameter of the intra-
myocardial arterioles among all the groups and greater media thick-
ness in the obese groups, which was reduced by the metformin
treatment. In the obese groups by observing an increased media-to-
lumen ratio which was reduced by metformin. Media cross-sectional
area was also increased in MSG groups compared to control groups
resulting in an elevated growth index suggesting in a hypertrophic
vascular remodeling in these animals (Table 1).
4.2. Cardiac collagen deposition
Interstitial connective tissue deposition in the perivascular region of
the left ventriclewas signiﬁcantly higher in the obese groupswhichwas
attenuated by metformin. Collagen deposition in the subendocardial
and subpericardial areas was also higher in MSG-treated rats but did
not reach statistical signiﬁcance (Table 1, Fig. 2).
5. Discusssion
To our knowledge, there is no consistent data about the structure
of small arteries in the heart of obese animals yet. The present studyen deposition in all groups.
CONT-22 MSG-22 MET-22
29.5±0.1 31.2±0.2⁎⁎⁎ 30.2±0.1##
1.13±0.21 2.62±0.43 2.24±0.23
35.9±2.3 34.7±2.4 33.9±1.3
10.9±0.4 14.5±0.6⁎ 11.5±1.0
29.5±1.2 39.8±1.3⁎ 31.5±0.9
10.9±0.4 14.5±0.6⁎ 11.5±1.0
– 33.0 5.5
4.0±0.3 4.8±0.8 3.0±0.1
2±0.4 4±0.5 4±0.5
0.83±0.06 1.39±0.06⁎⁎ 1.02±0.04
Fig. 1. Systolic blood pressure (BP) (A), plasma glucose (B), plasma insulin (C) and Homeostasis Model Assessment (HOMA-IR) (D) in all groups. Results are presented as mean±SEM.
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myocardial arterioles and cardiac ﬁbrosis associated with obesity and
insulin resistance. More importantly, these structural cardiovascular
changes were attenuated by metformin treatment.
Insulin resistance has been recognized as an important risk factor
for the development of cardiovascular disease. It has been previously
estimated that nearly 70% of patients with coronary artery disease
have some form of glucose intolerance [17]. This indicates that diabe-
tes and cardiovascular disease may share an underlying cause.
MSG-treated rat is a model of obesity characterized by insulin resis-
tance associated or not with hypertension, depending on the animal's
age [11]. In this study, there was no signiﬁcant difference in systolic
BP of obese animals in comparison with corresponding controls.
However, the notable BP increase in older MSG-treated rats com-
pared to younger animals conﬁrms that obesity may not initiallyFig. 2. Representative images of optical microscopy showing interstitial (upper images) and
ratio of intramyocardial arterioles may also be observed in MSG groups.change BP but hypertension can develop after a short time. Increased
plasma levels of corticosterone might contribute to BP raise in this
model [18]. Moreover, a recent study demonstrated an association
between increased BP and products of COX-2 in MSG-treated rats, in-
dicating a possible role for prostaglandins in the interaction of hyper-
tension with inﬂammatory process in MSG-induced obesity [19].
It has been recently shown that severe human obesity is associated
with changes in the structure and function of small arteries. Indepen-
dently from the presence of hypertension and diabetes, obese patients
have shown to present increased media-to-lumen ratio and increased
media cross-sectional area of subcutaneous small resistance arteries
[9]. These data indicate that obesity is associated with structural vas-
cular changes, mainly characterized by hypertrophic vascular remo-
deling. In agreement with this, the present study evidenced an
increased media cross-sectional area of intramyocardial arterioles inperivascular (lower images) collagen density in all groups. Increased media-to-lumen
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hypertrophic vascular remodeling in the heart of these animals. The
mechanism bywhich obesity, insulin resistance and/or hyperinsuline-
mia determine vascular disease is not clear yet. The hypertrophic
remodeling observed in our study could be attributed to the prolifera-
tive effects of insulin on vascular smooth muscle cells [20,21]. The in-
creased release of norepinephrine associated with visceral obesity
may also promote vascular hypertrophy [22,23]. In addition, a chronic
state of low-grade inﬂammation residing in the adipose tissue pro-
vokes inhibitory effects on insulin sensitivity in the liver and peripher-
al tissues, and increased release of proinﬂammatory cytokines by
adipose tissue could promote vascular wall inﬂammation and hyper-
trophic response [24]. Visceral adipose tissue can produce numerous
cytokines, such as monocyte chemoattractant protein 1 (MCP-1) and
interleukin-6 (IL-6) which were correlated with epicardial fat thick-
ness, and may contribute to diastolic dysfunction in obese patients
[25–27].
In the current study, vascular remodeling was assessed in young
rats. This was intentionally done in order to evaluate early vascular
disease associated with obesity. Indeed, obesity in adolescent and
young adult men has already been associated with early atheroscle-
rotic lesions [28]. Moreover, long-term follow-up studies have con-
ﬁrmed that obesity in youth predicts cardiovascular morbidity and
mortality [29,30]. Many authors have assumed that hyperinsuline-
mia, as a compensatory mechanism arising from elevated insulin re-
sistance, is responsible for increased cardiovascular risk, but the
evidences of this relationship have been inconsistent [31,32]. In fact,
HOMA-IR and other insulin resistance indexes, rather than insulin
concentrations per se, have been more associated with cardiovascular
risk and outcomes [33].
The increased collagen deposition in the perivascular area of the
left ventricle in MSG-treated animals in this study indicated initial
process of cardiac ﬁbrosis induced by obesity and/or insulin resis-
tance. Accordingly, increased interstitial ﬁbrosis has been described
in the heart of different animal models of obesity such as Zucker rats
and transgenic mice [34,35]. In ob/ob mice, ﬁbrosis was observed
mainly in the perivascular region as we evidenced in our obese rats.
The mechanisms are not known but the ﬁbrotic response may be in
part due to local activation of the renin–angiotensin system as treat-
ment of animals with angiotensin converting enzyme inhibitors result
in regression of ﬁbrosis [36,37]. Replacement ﬁbrosis might follow ap-
optotic cardiomyocyte death but a recent study using high-fat diet-
induced insulin resistant ratmodel of obesity did not detect signiﬁcant
differences in apoptosis despite cardiomyocyte dysfunction [38]. At
last, regulation of myocardial extracellular matrix by adipokines may
play a role in obesity [39]. Serummarkers of cardiac collagen turnover
have been shown to be elevated in obese individuals and increased
matrix metalloproteinase-9 activity in the left ventricle seems to be
an early trigger of adverse cardiac remodeling [40,41]. Furthermore,
leptin signaling may also contribute to cardiac extracellular matrix
regulation in obesity since leptin was able to increase procollagen
types III and IV although not changing total collagen synthesis [42].
The most remarkable ﬁnding in our study was the beneﬁcial effect
of metformin in reducing vascular remodeling and attenuating cardiac
collagen deposition. In fact, pharmacological sensitizers have been
shown to reverse myocardial insulin resistance and thus reducing
myocardial injury [43,44]. The cardioprotective effects of metformin
have been lately attributed to the inhibition of collagen synthesis by
cardiac ﬁbroblasts through impairment of transforming growth factor
(TGF)-beta [1] and reductions in circulating andmyocardium levels of
tumor necrosis factor-α [45,46]. It has recently reported an improve-
ment of cardiac structure and function provoked by metformin
whichwas associatedwith increased nitric oxide production and inhi-
bition of protein synthesis induced by angiotensin II in cardiomyo-
cytes [47]. Anti-inﬂammatory effects could also be speculated for
insulin sensitizers although there is no conﬁrmatory evidence.Reductions in pro-inﬂammatory cytokines and monocyte adhesion
molecules, and improved glycation status may beneﬁt endothelial
function in the macro- and microvasculature [48]. In A Diabetes Out-
come Progression Trial (ADOPT), metformin was able to reduce
C-reactive protein but this favorable outcome was correlated with
changes in weight [49]. In randomized controlled trials, metformin
seemed to be moderately effective in reducing body mass index and
insulin resistance in non-diabetic hyperinsulinemic obese children
and adolescents in the short term [50,51]. Regardless of improving
metabolic abnormalities, a direct effect ofmetformin on vascular func-
tion has been proposed by some authors [13,52]. On the other hand, it
has recently shown that metformin had no inhibitory effect on human
vascular smooth muscle cell proliferation assessed by thymidine in-
corporation and cell counting [53]. Plasma glucose levels were very
similar among all the groups in the current study. This ﬁnding sup-
ports an apparent vasoprotective effect of metformin independent of
blood glucose-lowering efﬁcacy.
The present study has some limitations that might interfere with
some results. The sample size may be considered small for deﬁnitive
conclusions. However, we used the sample of ﬁve animals per group
according to established pattern for quantitative studies. The age of
the animals probably attenuated some of the study results. Older
rats might have presented increased blood pressure and more intense
pathologic changes in the heart and vessels. However, the actual ob-
jective of this study was to evaluate the effects of metformin on
young obese animals in a prediabetic status with no cardiovascular
change attributed to hypertension. Lastly, the duration of metformin
treatment may have inﬂuenced some ﬁndings. Most likely, shorter
treatment would have no effect on cardiac and vascular structure.
On the other hand, we do not know whether longer use of metformin
would provoke some beneﬁcial results, but this was not in the scope of
this study.
In conclusion, hypertrophic vascular remodeling and cardiac colla-
gen deposition were signiﬁcantly evident in MSG-induced obese rats.
Metformin treatment was able to reduce insulin resistance and atten-
uated this adverse cardiac and vascular remodeling. Further studies
are necessary to identify the exact mechanisms involved in these
pathological alterations and to correlate with unfavorable outcomes.
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